Why Eli Lilly Stock Flopped on Friday
Why Eli Lilly Stock Flopped on Friday
Eric Volkman, The Motley FoolFri, April 24, 2026 at 10:50 PM UTC
0
Key Points -
Foundayo's initial prescription count was notably lower than that of its rival.
This is Eli Lilly's first FDA-approved weight-loss pill.
10 stocks we like better than Eli Lilly ›
Doubts about a high-profile new product dampened investor enthusiasm for Eli Lilly (NYSE: LLY) stock on Friday. The giant pharmaceutical company didn't have a good trading session, with sell-offs driving its price down by almost 4% over the course of the day.
Tough pill to swallow?
The product in question is Eli Lilly's Foundayo, the company's first pill approved by the U.S. Food and Drug Administration (FDA) for weight loss. Hopes were high for the drug, particularly given the success of Zepbound, the obesity treatment administered by injection that's been a hot seller for the company.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Person checking medicine on a shelf in a pharmacy.
Image source: Getty Images.
Foundayo might not be destined for similar success. Media reports indicated that the drug's initial sales are comparatively sluggish. Reuters, citing data from Iqvia Holdings provided to stock analysts, wrote that it was prescribed 3,707 times in the work week ended Friday, April 17.
Although that was well up from the 1,390 in the previous week -- its first, following FDA approval -- the numbers pale in comparison to its archrival. This is Novo Nordisk's Wegovy pill, the first-mover orally administered obesity treatment that earned its FDA green light last December. It clocked 18,410 prescriptions in its second week on the market.
Lilly previously said that Foundayo's weekly data might not be comprehensive. It added that the drug's performance might be "best interpreted over time rather than as a complete count."
One product of many
While that might be true, we should remember that Zepbound (also a second mover, following the FDA's historic approval for injectable Wegovy in June 2021) was a hot product out of the gate. So Foundayo's relatively low sales are justifiably concerning, and it's well worth monitoring the drug's trajectory over the coming weeks for signs of improvement.
Advertisement
Having said that, Lilly is a monster of a pharmaceutical company with a dizzying number of products. Yes, it's done well with Zepbound, but it's far from dependent on the closely scrutinized weight loss category. I wouldn't be so discouraged by Foundayo's early numbers, then.
Should you buy stock in Eli Lilly right now?
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $500,572!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,223,900!*
Now, it’s worth noting Stock Advisor’s total average return is 967% — a market-crushing outperformance compared to 199% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 24, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iqvia Holdings. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Source: “AOL Money”
